Information

Dear user, the application need JavaScript support. Please enable JavaScript in your browser.

Title of the item:

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

Title:
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
Authors:
Oxnard, G.R.
Yang, J.C.-H.
Yu, H.
Kim, S.-W.
Saka, H.
Horn, L.
Goto, K.
Ohe, Y.
Mann, H.
Thress, K.S.
Frigault, M.M.
Vishwanathan, K.
Ghiorghiu, D.
Ramalingam, S.S.
Ahn, M.-J.
Source:
In Annals of Oncology April 2020 31(4):507-516
Academic Journal

We use cookies to help identify your computer so we can tailor your user experience, track shopping basket contents and remember where you are in the order process.